Brainlab increases its investment in Nexstim

The investment supports the continued commercialization of the NBS System 6* platform. With the recent launch of this system, Brainlab and Nexstim can now offer neurosurgery customers an integrated workflow spanning from navigated transcranial magnetic stimulation (nTMS) to planning and surgery. 

Rainer Birkenbach, CEO of Brainlab, commented: “Building on our close collaboration with Nexstim, this investment underlines our firm belief in the long-term success of nTMS. Since entering the partnership in 2024, increasing momentum has been driven by its clear clinical value. With the recent launch of NBS 6, neurosurgery customers can benefit from an integrated workflow spanning from nTMS to planning and surgery. Together, Brainlab and Nexstim will continue to advance the technology and strengthen its relevance for customers worldwide, with a meaningful impact on patient outcomes.” 

Mikko Karvinen, CEO of Nexstim, added: “Brainlab’s continued support both as an investor and as a promoter of Nexstim’s diagnostics business is greatly appreciated. The announced arrangement expands Nexstim’s shareholder base with an internationally recognized European growth investor, strengthening the company’s financial position for the next phases in the execution of its profitable growth strategy.” 

For more information, read the official announcement: https://www.nexstim.com/investors/releases?publicationId=ba31cfc4-bd80-4e73-b946-a684aa716d06 

More information on our website: https://www.brainlab.com/surgery-products/overview-platform-products/nexstim-nbs-system/ 

*Not yet commercially available in several countries. Please contact your sales representative.